Incyte Operating Cash Flow decreased by 32.0% to $369.35M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 38.8%, from $266.07M to $369.35M. Over 4 years (FY 2021 to FY 2025), Operating Cash Flow shows an upward trend with a 17.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates strong operational efficiency and cash generation, while a decrease may signal operational challenges or issues with working capital management.
This metric represents the total cash generated or consumed by a company's core business operations during a specific pe...
Standard across all industries; peers in the medical device and diagnostics sector typically maintain high conversion ratios of net income to operating cash flow.
net_cash_from_operating| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $172.94M | $255.10M | $115.35M | $215.74M | $174.16M | $296.38M | $283.66M | -$105.60M | $306.53M | $147.84M | $147.73M | $218.81M | -$575.56M | $310.87M | $381.22M | $266.07M | $44.74M | $559.39M | $543.30M | $369.35M |
| QoQ Change | — | +47.5% | -54.8% | +87.0% | -19.3% | +70.2% | -4.3% | -137.2% | +390.3% | -51.8% | -0.1% | +48.1% | -363.0% | +154.0% | +22.6% | -30.2% | -83.2% | >999% | -2.9% | -32.0% |
| YoY Change | — | — | — | — | +0.7% | +16.2% | +145.9% | -148.9% | +76.0% | -50.1% | -47.9% | +307.2% | -287.8% | +110.3% | +158.1% | +21.6% | +107.8% | +79.9% | +42.5% | +38.8% |